Harnessing Single Cell Technology to Define Self-Renewal in Normal and Malignant Stem Cells
Harnessing Single Cell Technology to Define Self-Renewal in Normal and Malignant Stem Cells
批准号:
9350788
负责人:
Jessica S. Blackburn
金额:
$229.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-22 至 2022-08-31
关键词:
Acute Lymphocytic LeukemiaAutomobile DrivingBiologyCancer BiologyCancer ModelCancer RelapseCell surfaceCellsClinicalDataDiseaseDrug DesignFrequenciesGene Expression ProfileGenomicsGoalsHematopoietic stem cellsHumanImpairmentLabelLeukemic CellMaintenanceMalignant NeoplasmsModelingNormal tissue morphologyOrganPatientsPharmaceutical PreparationsPopulationPreclinical Drug EvaluationRelapseResearch PersonnelRoleSamplingStem cellsTechnologyTissuesTranslatingTransplantationZebrafishbasebiomarker panelcancer stem cellcell typechemotherapyin vivoleukemiamouse modelneoplastic celloutcome forecastpatient subsetspreventself renewing cellself-renewalsingle cell sequencingsingle cell technologystem cell nichesuccesstranscriptome sequencingtumortumor progression
中文摘要
!
英文摘要
!
Project Summary
A major clinical issue in most cancers is relapse. Patients often respond very well to
chemotherapy, and can go years without any sign of disease, but a subset of patients will invariably re-
develop their cancer with a poor final prognosis. Relapse occurs because our current chemotherapies
are unable to reliably and completely eliminate tumor propagating cells, also known as cancer stem cells.
These cells are unique among the tumor cell population in that they can self-renew, meaning that they
can replenish a tumor cell population indefinitely, similar to the role of the normal tissue stem cells in
tissue and organ maintenance. Preventing self-renewal in tumor propagating cells would cause them to
terminally differentiate, thereby blocking their ability to form relapse. Unfortunately, self-renewal of tumor
propagating cells is not well understood, precluding rational drug design. A major issue in regards to
studying these cells is their rarity; they often comprise 1 in every 105-107 cells within the total tumor cell
population in human cancers and mouse models, and culture ex vivo alters their self-renewal capability.
Researchers necessarily rely on FACS enrichment based on certain cell surface markers, but this biases
towards the cells expressing the markers and excludes some subsets of self-renewing cells.
The goal of this project is to have a major impact in the biomedical field by defining self-renewal
in tumor propagating cells in a completely unbiased manner. We will use leukemia propagating cells as a
model and determine how these cells differ from normal hematopoeitic stem cells, which can also self-
renew, and how are they unique from other leukemic cells that cannot self-renew. Based on these data,
we will find ways to detect leukemia propagating cells in patients, and identify drugs that can inhibit their
self-renewal ability. Initially, we will use a panel of high self-renewing acute lymphoblastic leukemias and
normal hematopoietic stem cells isolated from zebrafish models, which will allow us to use single cell
RNA sequencing to identify the unique gene expression profile of self-renewing leukemia propagating
cells without the need for FACS enrichment. We will translate our findings to human cells to build a
biomarker panel that can detect the frequency of self-renewing cells in patient samples, and tell us
whether chemotherapy has successfully eliminated them. We will also characterize the stem cell niche in
leukemias with high and low self-renewal rates, to identify how the niche is regulating self-renewal rate.
Finally, we will use transplantation approaches in zebrafish, as well as new zebrafish models in which the
leukemia propagating cells are fluorescently labeled, for high-throughput, in vivo drug screens to identify
compounds that impair self-renewal. In total, this project will provide an unbiased genomic and functional
analysis of tumor propagating cells, allowing us to answer fundamental questions about the biology of
this important tumor cell type.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Phosphatase PRL3 as a MYC Target and Pro-Survival Oncogene in Acute Lymphoblastic Leukemia
-
批准号:10527104
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2023
-
负责人:Jessica S. Blackburn
-
依托单位:
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
-
批准号:9904131
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2018
-
负责人:Jessica S. Blackburn
-
依托单位:
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
-
批准号:10376861
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2018
-
负责人:Jessica S. Blackburn
-
依托单位:
The Role of Protein Tyrosine Phosphate PRL3 in Leukemia Development
-
批准号:9193624
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2015
-
负责人:Jessica S. Blackburn
-
依托单位:
The role of the protein tyrosine phosphatase PRL3 in leukemia development
-
批准号:8618454
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2014
-
负责人:Jessica S. Blackburn
-
依托单位:
The role of the protein tyrosine phosphatase PRL3 in leukemia development
-
批准号:8792374
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2014
-
负责人:Jessica S. Blackburn
-
依托单位:
海外基金